Trastuzumab for HER2 Positive Breast Cancer: 78 Real Stories

Triple receptor-positive neuroendocrine breast cancer in a 32-year-old woman

Patient Info: Anonymized, Female, Under 40 | Stage III

Biomarkers: ER positive; PR positive; HER2 positive; neuron-specific enolase positive; synaptophysin positive

She was stable on follow-up and was receiving adjuvant chest-wall radiation plus systemic chemotherapy and trastuzumab-based therapy.

PubMed CentralRead more →

HER2-Positive Inflammatory Breast Cancer: Trish's Patient Story

Patient Info: Trish Vickery, female, 50s

Biomarkers: HER2-positive

At 58, Trish was living an active life after treatment, including working, traveling, exercising, and rowing.

Dana-FarberRead more →

Stage IV HER2-Positive Breast Cancer: Sarah's Patient Story

Patient Info: Sarah, Female, Under 40 | Stage IV

Biomarkers: HER2-positive; BRCA and other known hereditary breast cancer genes not identified in family history discussion

As of January 2017, Sarah had been living for almost 3 years with recurrent Stage IV HER2-positive breast cancer and was receiving Kadcyla every 3 weeks.

YouTube — Oncology AssociatesRead more →

Stage III Inflammatory Breast Cancer Diagnosed After Severe Breast Pain and Swelling Following Mammography

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: ER negative, PR negative, HER2 highly positive

After later metastatic disease was found, she chose no further active treatment and died of progressive disease in 2012.

PubMed CentralRead more →

HER2-Positive Right Breast Cancer With Complete Response Before Bilateral Mastectomy

Patient Info: Anonymized, female, 50s

Biomarkers: ER negative, PR negative, HER2 positive

After neoadjuvant treatment, imaging showed complete resolution of the right-breast mass and mastectomy pathology found no residual right-breast tumor or malignant right sentinel node.

PubMed CentralRead more →

Recurrent HER2-amplified breast cancer: complete remission on trastuzumab-based therapy

Patient Info: Anonymized, Female, 40s | Stage Metastatic/Advanced

Biomarkers: Primary tumor was ER/PR negative and HER2 not amplified. Recurrent lymph-node disease became ER/PR positive and HER2 amplified by FISH.

Metastatic Site: left axillary and infraclavicular lymph nodes

After HER2-amplified nodal recurrence, paclitaxel plus trastuzumab produced complete clinical remission; she continued trastuzumab monotherapy with tolerable neuropathy.

PubMed CentralRead more →